GlassScriptPhysician profile
Edward Kobraei
NPI 1750647863
$78,271.36
in general payments reported to CMS, 2019-2025
7 companies · $77K in 2025
The $77K reported for 2025 was more than what 99% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2024: $910 · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $75K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,482 · Education: $1,075 · Food and Beverage: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $75,346.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,482.00 |
| Education | $1,075.00 |
| Food and Beverage | $204.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tulavi Therapeutics, INC. | $73,716.00 | 2025 | Allay Nerve Cap - Small Nerve Set |
| Stryker Corporation | $2,000.00 | 2025 | |
| W. L. Gore & Associates, INC. | $1,482.00 | 2025 | Product In Development |
| Becton, Dickinson and Company | $705.00 | 2024 | |
| Axogen | $177.34 | 2019-2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Ha+ Nerve Protector |
| Checkpoint Surgical, INC | $101.03 | 2024 | Checkpoint Stimulators |
| Endo Pharmaceuticals INC. | $89.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,600.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kobraei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.